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ABSTRACT
Background and Objectives: To avoid the risk of developing contrast-induced nephropathy (CIN), it has been suggested 
that patients be subjected to a minimal necessary dose of contrast medium (CM-dose). However, often it is not easy to deter-
mine such a dose. This study assessed the usefulness of the ratio of CM-dose to estimated glomerular filtration rate (eGFR) in 
predicting the risks of CIN and sought to determine the safe level of CM-dose/eGFR in patients undergoing non-emergent 
percutaneous coronary intervention (PCI). Subjects and Methods: We enrolled a total of 226 patients and calculated the 
ratio of CM-dose using grams of iodine (g-I) to eGFR, thus expressing it as g-I/eGFR. Among the CIN patients, those with ne-
phropathy requiring dialysis (NRD) were also evaluated. Results: Overall, there were 16 cases (7.1%) of CIN. On univariate 
and multivariate regression analysis, g-I/eGFR alone was found to be an independent predictor for CIN (hazard ratio=10.73, 
p<0.001). In an receiver operating characteristic analysis, fair discrimination for CIN was found at a g-I/eGFR level of 1.42 (C 
statics=0.867), and at this value, the sensitivity and specificity were 81.3% and 80%, respectively. Of patients (n=51) with g-I/
eGFR ≥1.42, 23.6% (13/51) and 7.8% (4/51) developed, while those with g-I/eGFR <1.42 (n=171) had a lower incidences of 
CIN (1.8%, 2/171, p<0.001) and NRD (0%, 0/171, p<0.001). Conclusion: It can be concluded that a g-I/eGFR <1.42 is a sim-
ple, useful indicator for determining the safe CM-dose based on the pre-PCI eGFR values. Furthermore, g-I/eGFR might have 
a close relationship with the development of NRD as well as CIN. (Korean Circ J 2011;41:265-271)
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Introduction
Contrast-induced nephropathy (CIN) has been commonly 
defined as a sudden, rapid deterioration in renal status after 
the administration of iodinated contrast medium (CM) in the 
absence of any other causes.
1)2) It had been reported that CIN 
is associated not only with an increased in-hospital morbidi-
ty and mortality but also a 1-year mortality; at least in con-
nection with percutaneous coronary intervention (PCI).
3-6) Ac-
cordingly, risks of developing CIN pose a major challenge for 
interventional cardiologists. Moreover, a considerable num-
ber of patients with cardiovascular disease have multiple risk 
factors for developing CIN, which include impaired renal 
function presented as glomerular filtration rate (GFR) <60 mL/
min/1.73 m
2, advanced age, diabetes mellitus, hemodynamic 
instability, anemia, volume depletion, nephrotoxic medica-
tions and an exposure to a large volume of CM.
1)3)4)7)8) Unfor-
tunately, a majority of these risk factors have been reported 
to be both preexisting and non-modifiable. Therefore, many 
patients who are candidates for PCI are prone to these inevi-
table multiple risk factors. 
Despite several positive studies, no preventive method oth-
er than hydration, has been convincingly shown to prevent 
CIN in high-risk patients.
9)10) Because the amount of CM is one 
of the major modifiable risk factors, it has been desirable that 
more acceptable methods be developed to assess the dose of 
CM (CM-dose) depending on risks to each patients. It has 266   How to Estimate Safe Contrast Media Dosage
been generally accepted that the risk of CIN increases with 
higher CM-dose and lower GFR.
11-16) It has also been specu-
lated that the risks of developing CIN are closely associated 
with the ratio of CM-dose to GFR. Accordingly, by combin-
ing the amount of CM with an estimated glomerular filtration 
rate (eGFR) into a single continuous risk factor, new methods 
have been developed.
12) Thus, the ratio of CM-dose to eGFR 
has been proposed to predict risks of developing CIN. 
Because commercially available CM has a varying concen-
tration of iodine ranging from 140 to 400 mg-I/mL, unpredic-
table errors have occurred while expressing the CM-dose 
with volume and thereby establishing a safe CM-dose. To cor-
rect this, the ratio of grams of iodine (g-I) to eGFR ratio (g-I/
eGFR) has been proposed as a breakthrough method in con-
trast to the conventional ratio of CM-dose to eGFR. To date, 
studies have been performed using g-I/eGFR in patients with 
acute myocardial infarction who had undergone primary 
PCI.
15) It remains questionable as to whether the ratio of g-I/
eGFR would be effective in predicting CIN in patients who 
had undergone elective PCI. Furthermore, even small volumes 
of CM in high-risk patients have been shown to cause CIN 
and threshold levels of CM are still being debated.
17) Addi-
tionally, few studies have been conducted to examine the 
correlations between safe amounts of CM and the status of 
renal function in patients who have undergone elective PCI, 
using g-I/eGFR. Given the background, we conducted this 
prospective study to assess the usefulness of the ratio of g-I/
eGFR in predicting the risk of developing CIN and to deter-
mine safe levels of g-I/eGFR in patients undergoing non-
emergency PCI.
Subjects and Methods
Patients
This study was conducted in a single-institution setting at 
a university hospital (Keimyung University Dongsan Hospi-
tal, Daegu, Korea) from April of 2008 to January of 2009. Eli-
gibility criteria were 19 years of age or older and a referral for 
coronary angiography (CAG) and PCI. Exclusion criteria were 
as follows: cardiogenic shock, pulmonary edema, emergent 
CAG, end-stage renal disease requiring dialysis, and previ-
ous administration of CM within 72 hours of PCI.
Study protocol 
One day before the CAG, blood and urine samples were col-
lected and the following biochemical markers were assessed: 
blood urea nitrogen (BUN), serum creatinine (Cr), hemoglo-
bin (Hb), hematocrit (Hct), high-sensitivity C-reactive protein 
(hs-CRP), total cholesterol, low density lipoprotein (LDL)-cho-
lesterol, and routine urinalysis. Follow-up laboratory tests 
were also performed for Hb, Hct, and BUN/Cr on days 1 
and 2 following the PCI. In patients who showed serum Cr 
elevation following the PCI, a follow-up laboratory test was 
performed. An estimated GFR was calculated as creatinine 
clearance by the Modified Diet in Renal Disease (MDRD) 
study equation.
18)19) A two dimensional echocardiography was 
obtained several days before the PCI and left ventricular ejec-
tion fraction (LVEF) was calculated using the biplane modi-
fied Simpson method. All patients were given the same hy-
dration regimen with intravenous isotonic saline at a rate of 
1 mL/kg/hr for 12 hours before and after PCI. However, the 
prophylactic use of medications (e.g., N-acetylcysteine) was not 
allowed in these patients. 
After informed consent was obtained, all procedures were 
done at the operator’s discretion. Both CAG and PCI were per-
formed as per the standard techniques, via either femoral or 
radial approach. All the patients received aspirin and clopi-
dogrel and they were also given glycoprotein IIb/IIIa recep-
tor blockers and heparin at the discretion of the operator. In 
the current study, we used either iso-osmolar, non-ionic CM, 
iodixanol (Visipaque
TM 320 mg-I/mL; GE Healthcare Korea, 
Seoul, Korea), or low-osmolar, non-ionic CM, iohexol (Bono-
rex
TM 350 mg I/mL; Dai Han Pharm, Seoul, Korea). The am-
ounts of delivered CM were measured using an automated 
contrast delivery injection system (ACIST
TM; ACIST Medi-
cal Systems, Inc, Minnesota, USA) with CM amount calcu-
lated as g-I. 
CIN was defined as a 25% elevation or an absolute in-
crease of >0.5 mg/dL (>44 umol/L) in the Cr level compared 
to baseline within 48 to 72 hours after PCI according to the 
definition of the CIN consensus working panel.
4) Any cases 
of CIN in which in-hospital renal replacement therapy was 
required due to severe nephropathy were labeled as nephrop-
athy requiring dialysis (NRD). The decision to initiate dialy-
sis was at the discretion of the consulting nephrologist.
Statistical analysis
All statistical analyses were performed with Statistical Pa-
ckage for the Social Sciences (SPSS, release 15.0; SPSS Inc., 
Chicago, IL, USA). To identify the correlations between CIN 
and the clinical and laboratory parameters, a univariate analy-
sis was done using the Mann-Whitney U-test. In addition, an-
alysis of variance and Chi-square tests were performed for 
continuous and categorical variables, respectively. We re-
garded a p<0.05 as statistically significant. A multivariate lo-
gistic regression analysis was used to assess the correlation 
among those parameters whose statistical significance was 
demonstrated through a univariate analysis at a level of p< 
0.05 and previously well-known risk factors, which did not 
show a significant difference in this study. Models were de-
veloped with stepwise techniques, for which results were ex-
pressed as odds ratios (OR) with 95% confidence intervals 
(CI). Finally, the g-I/eGFR ratio was added to the model as a 
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dose and eGFR. Interactions between variables were investi-
gated and g-I/eGFR showed significant correlations with se-
rum Cr, eGFR, and CM dose. Therefore, we choose g-I/eGFR 
as a single variable on behalf of variables according to kid-
ney function and CM dose. A receiver operating characteris-
tic (ROC) curve was plotted and the area under the curve was 
calculated. This was used as an overall measure of CIN clas-
sification ability in the final regression model. 
Results
Clinical and laboratory characteristics of the patients
A total of 466 consecutive patients were referred for CAG 
and PCI, and were subsequently screened between May 2008 
and January 2009. Of these, 226 patients were eligible for this 
study. One hundred thirty-six patients with primary PCI or 
emergency PCI, 18 patients with renal replacement therapy, 
and 53 patients with a history of CM exposure within 72 hours 
due to multi-detector coronary computerized tomography 
were excluded based on exclusion criteria. 
The study group was composed of 151 men and 75 women 
(63.7±11.0 years). Of the final 226 patients, CIN occurred in 
16 patients (7.1%). Patients were divided into two groups 
based on the development of CIN: the CIN group (n=16) 
and the non-CIN group (n=210). Table 1 represents baseline 
characteristics of both groups of patients.
The age and the incidence of hypertension were signifi-
cantly higher in the CIN group. Further, of the baseline lab-
oratory findings, the CIN group had a significantly lower 
degree of Hb and eGFR levels, a significantly higher degree 
of BUN and creatinine levels, and a significantly higher pre-
valence of positive urine protein dipstick results compared 
with the non-CIN group. The CIN group were also subjected 
to a higher dose of CM (g-I) and had a higher ratio of g-I/eGFR 
as compared with the non-CIN group. In the current study, 
there was no significant correlation between the types of de-
livered CM and the development of CIN.
Predictors of contrast-induced nephropathy
As shown in Table 2, upon univariate logistic regression 
analysis, age, usage of intraaortic balloon pump, hyperten-
sion, LVEF, Hb level, and g-I/eGFR were significantly corre-
lated with the development of CIN. Although a history of di-
abetes was not within the range of statistical significance, it 
had a close correlation with the development of CIN (p= 
0.051). On multivariate analysis, only the ratio of g-I/eGFR 
remained as a significant independent risk factors for the 
development of CIN (g-I/eGFR, OR 9.786, 95% CI 3.40-
28.15, p<0.001) (Table 2). In the analysis using g-I/eGFR ra-
tio, quartiles showed a gradual increase in the incidence of 
CIN in quartiles III and IV. On the other hand, in quartiles I 
and II, the incidence of CIN were significantly lower than 
those of quartiles III and IV (Fig. 1).
We analyzed g-I/eGFR to assess the predictive value of CIN 
using an ROC curve (Fig. 2). Results indicated that g-I/eGFR 
had a strong predictive value on the ROC curve (area under 
the curve=0.867). Further, the ROC curve analysis showed 
fair discrimination between the two groups at a g-I/eGFR 
level of 1.42. At this value, the sensitivity and specificity for 
development of CIN were 81.3% and 80%, respectively. 
Of the patients (n=55) with g-I/eGFR ≥1.42, 23.6% (13/55) 
developed CIN while those with a g-I/eGFR <1.42 had a lo-
wer incidence of CIN (1.8%, 3/171; p<0.001) (Fig. 3).
Impact of contrast-induced nephropathy on clinical 
course and outcome
Of the 16 patients with CIN, 75% (12/16) had a transient 
Table 1. Baseline demographic data for the CIN and non-CIN pa-
tients 
CIN
(n=16)
Non-CIN
(n=210)
p
Age (years) 69.7±11.3 063.2±10.9 0.028
Male (%) 67.6 56.3 0.411
Body weight (kg) 62.8±11.1 64.9±9.9 0.758
Height (cm) 159.1±9.600 162.5±8.40 0.156
Diabetes mellitus (%) 56.3 31.6 0.055
Hypertension (%) 75.0 36.4 0.037
Diagnosis
   Stable/Unstable, ACS (%) 56.3/43.7 52.7/47.3 0.445
IABP (%) 12.5 01.0 0.026
LVEF (%) 50.0±16.3 056.5±11.1 0.110
Hb (g/dL) 11.5±2.10 12.9±1.6 0.007
BUN (mg/dL) 23.9±7.40 17.6±6.2 <0.001
Creatinine (mg/dL) 1.5±0.5 01.2±0.2 <0.001
eGFR (mL/min/1.73 m
2)
   By MDRD  46.2±18.1 065.1±13.7 <0.001
Urine protein (+) (%) 43.8 13.2 0.005
Total cholesterol (mg/dL) 180.5±55.00 0190.9±131.5 0.300
LDL-cholesterol (mg/dL) 114.8±42.60 0126.9±113.0 0.324
HDL-cholesterol (mg/dL) 40.4±4.50 045.2±27.5 0.227
Type of CM (n)
   Iodixanol/Iohexol  4/12 58/152 0.898
Contrast amounts (mL) 300.6±145.7 204.1±91.3 0.004
Grams Iodine (g) 102.4±48.10 069.6±30.8 0.003
g-I/eGFR (g/mL/min/ 
   1.73 m
2)
2.5±1.3 01.1±0.5 <0.001
Values are mean±SD. CIN: contrast-induced nephropathy, IABP: in-
tra-aortic balloon pump, LVEF: left ventricular ejection fraction, eGFR: 
estimated glomerular filtration rate, MDRD: equation of modified diet 
on renal disease study group, LDL: low density lipoprotein, HDL: high 
density lipoprotein, CM: contrast media, g-I/eGFR: ratio of delivered 
contrast media by grams of iodine and estimated glomerular filtra-
tion rate, ACS: acute coronary syndrome, BUN: blood urea nitrogen268   How to Estimate Safe Contrast Media Dosage
impairment of renal function and then subsequently achieved 
spontaneous recovery; however, 25% (4/16) of them exhibit-
ed a critical clinical course and progressed to NRD, all of 
whom were started on renal replacement therapy. In our se-
ries, overall hospital mortality was 1.3% (3/226) and the in 
hospital mortality rate in the CIN group was 18.8% (3/16). 
Moreover, all cases of in-hospital mortality were associated 
with NRD. In other CIN cases, clinical outcomes were favor-
able and the renal function improved within a week to several 
months. Patients with CIN are commonly divided into two 
subgroups according to whether they were in need of dialysis: 
the non-NRD CIN group and the NRD group. In the current 
study, patients enrolled were divided into three groups: the 
non-CIN group (n=210), the non-NRD CIN group (n=12) and 
NRD-CIN group (n=4). 
There was a significant difference in the g-I/eGFR level 
among the three groups. The mean g-I/eGFR level was 1.10 
±0.48 in the non-CIN group, 2.19±1.24 in the non-NRD CIN 
group and 3.35±1.46 in the NRD-CIN group. These results 
indicate that there was a gradual increased in the mean g-I/
eGFR level in all three groups depending on the clinical fea-
tures of CIN (non-CIN group vs. non-NRD CIN group, p< 
0.001; non-CIN group vs. NRD-CIN group, p<0.001; non-
NRD CIN group vs. NRD-CIN group, p=0.002) (Fig. 4). Fur-
thermore, all cases of NRD were consistently found to devel-
op at a level of g-I/eGFR ≥1.42 based on the above-mention-
ed analysis of the ROC (Fig. 2).
Discussion
According to the results of the current prospective, obser-
vational study, it can be inferred that the ratio of g-I/eGFR 
may be the most significant predictor of CIN as compared 
with other previous well-known predictors. Besides, a close 
Table 2. Risk factors for CIN based on univariate and multivariate analyses
Univariate analysis Multivariate analysis
Hazard ratio p Confidence interval Hazard ratio p Confidence interval
Age 01.06 0.026 1.01-1.120 00.99 0.857 0.93-1.060
IABP 14.86 0.009 01.95-113.50 00.79 0.927 0.03-23.23
Diabetes 02.79 0.051 1.00-7.800 02.39 0.231 0.58-9.920
Hypertension 03.46 0.036 1.08-11.09 03.29 0.219 0.57-9.560
LVEF 00.95 0.039 0.92-0.990 00.97 0.187 0.92-1.020
Hb 00.58 0.002 0.41-0.810 00.72 0.143 0.46-1.120
Urine protein (+)  5.272 0.002 1.813-15.325 04.01 0.080 0.85-19.04
g-I/eGFR 09.28 <0.001 3.68-23.39 10.73 <0.001 3.27-35.23
CIN: contrast-induced nephropathy, IABP: intra-aortic balloon pump, LVEF: left ventricular ejection fraction, Hb: hemoglobin, g-I/eGFR: ratio 
of delivered contrast media by grams of iodine and estimated glomerular filtration rate
Fig. 1. Incidence of CIN according to quartiles of g-I/eGFR. Incid-
ence of CIN is markedly higher in quartiles III and IV compared with 
quartiles I and II. CIN: contrast-induced nephropathy, g-I/eGFR: ra-
tio of delivered contrast media by grams of iodine and estimated 
glomerular filtration rate.
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relationship was established between the ratio of g-I/eGFR, 
the incidence of CIN, and the clinical course of renal com-
plication after PCI. In our series, there was a significant cor-
relation between the ration of g-I/eGFR and the incidence of 
CIN irrespective of other combined risk factors. It can there-
fore be concluded that the ratio of g-I/eGFR is a simple, use-
ful indicator for determining the safe dose of CM based on 
the pre-procedural eGFR values for elective PCI. 
 
Estimation of a safe dose of contrast medium 
for elective percutaneous coronary intervention
Patients with multiple non-modifiable risk factors of de-
veloping CIN have been subjected to the minimal necessary 
dose of CM; however, the definition of an acceptable CM-dose 
for individual patients has been unclear. Of numerous risk 
factors for developing CIN, the CM-dose is a potentially mo-
difiable one that can be controlled at the discretion of opera-
tors. Determination of a safe dose of CM based on the ratio 
of g-I/eGFR level would therefore be mandatory for estab-
lishing the acceptable CM-dose prior to PCI in individual pa-
tients. 
The term CM/eGFR has been coined based on a pharma-
cotoxic mechanism: the CM-dose displays a positive correl-
ation with the systemic exposure to CM and a negative cor-
relation with the systemic clearance.
20) The increased amount 
of CM and the decreased level of eGFR are closely associated 
with the development of CIN. Accordingly, a formula based 
on the ratio of the estimated CM-dose to eGFR might have 
a prognostic value in predicting risks for developing CIN. 
To date, many efforts have been made to estimate a safe 
CM-dose using the above pharmacotoxic models. In 1989, 
Cigarroa et al.
11) proposed a formula, according to which the 
maximal safe CM-dose was determined using {the volume 
of CM/body weight (kg)} solely based on the concentration 
of Cr. Recently, more accurate estimations of renal function 
have become possible using Cockcroft-Gault and MDRD 
equations.
18)19)21) Since the CM-dose/eGFR was first intro-
duced,
12) clinical studies have been conducted in 3,179 unse-
lected patients undergoing PCI, and these studies reported 
that CM volume/eGFR of <3.7 might be a useful indicator in 
determining the volume of CM that would not trigger the 
occurrence of CIN.
14) 
With respect to CM-dose, grams iodine is the preferred ex-
pression because various concentrations of iodine contained 
in a CM are used for CAG ranging from 140 to 400 mg-I/
mL. Therefore, g-I/eGFR has been proposed as an alterna-
tive to the conventional CM-dose/eGFR ratio. Thus, the ex-
perience of CIN from one type of CM to another could be ex-
panded based on the idea of expressing the dose of g-I.
15) 
In our series, the safe g-I/eGFR ratio was 1.42 which was so-
mewhat higher than the value 1.0 previously reported from 
patients who had undergone primary PCI due to acute myo-
cardial infarction.
22) Our clinical series of cases consisted of 
controlled patients who were scheduled for elective PCI with 
appropriate hydration without other nephrotoxic agents. 
Little data is available from selective studies of CIN in cases 
of elective PCI using g-I/eGFR. Contrary to primary PCI 
cases, in scheduled PCI physicians can obtain sufficient in-
formation for safe CM-dose estimation prior to the proce-
dure. Therefore, results of the current study have more potent 
clinical implications than previous studies. 
 
Clinical implications of grams of iodine/estimated 
glomerular filtration rate associated with 
the development of contrast-induced 
nephropathy and nephropathy requiring dialysis
Of clinical importance, a g-I/eGFR ratio of 1.42 was also 
significantly correlated with a risk of developing NRD. CIN 
has a variable degree of clinical courses and outcomes. In oth-
er words, most cases of CIN have shown a mild transient im-
pairment of renal function and benign clinical course, alth-
ough a smaller number of patients had critical renal function 
Fig. 3. Depiction of the incidence for CIN and NRD according to g-I/ 
eGFR. Of patients with g-I/eGFR ≥1.42, there were significantly hi-
gher incidences of CIN and NRD compared with patients with g-I/
eGFR <1.42 (p<0.001). CIN: contrast-induced nephropathy, NRD: 
nephropathy requiring dialysis, g-I/eGFR: ratio of delivered contrast 
media by grams of iodine and estimated glomerular filtration rate.
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deteriorated and were therefore, in need of renal replacement 
therapy (NRD). Moreover, it has also been reported that this 
critical form of CIN is associated with a higher degree of in-
hospital mortality.
3) In this study, there was a significant cor-
relation of the g-I/eGFR level and the clinical courses of re-
nal complication after PCI. In patients with a g-I/eGFR level 
≥1.42, the incidence of CIN was 23.6% and that of NRD was 
7.3%, with an in-hospital mortality rate of 5.9%. However, in 
patients with a g-I/eGFR <1.42, CIN occurred at an incidence 
2.8% and none presented an NRD or an in-hospital mortality.
Clinical implications of the current study are that g-I/eGFR 
may represent a useful predictor for the occurrence of CIN 
and its clinical course after CIN. Therefore, a more careful 
consideration of a safe CM-dose should be mandatory in 
patients who are at increased risk for developing CIN based 
on a decreased eGFR prior to the PCI. Often, it has been the 
case that PCI treatment for complex lesions is associated 
with a large amount of CM administration. In these high-
risk patients, we should consider the g-I/eGFR ratios and 
then maintain the CM-dose consistently lest it should ex-
ceed the CM-dose. In some cases, staged procedures should 
also be considered to minimize the chance for CIN.
A pre-interventional determination of an adequate CM-
dose, based on the ratio of the g-I/eGFR, might be helpful in 
preventing CIN and NRD.
 
Limitations
Limitations of the current study are as follows.
Two different types of CM were used: non-ionic low-os-
molar contrast media, iohexol and iso-osmolar contrast me-
dia, iodixanol and the selection CM was not randomized. 
Accordingly, there is an inevitable operator bias in the choice 
of CM. However, the current study was not meant to exam-
ine the relationship between the type of CM and risks of CIN 
and further, there was no significant difference of incidence 
of CIN according to type of CM. As compared with ionic 
high-osmolar contrast media, non-ionic low-osmolar con-
trast media (LOCM) has shown a less frequent development 
of CIN.
23) Further, there is still a controversy as to whether 
iso-osmolar contrast media (IOCM) provides benefit over 
LOCM, although patients with both chronic renal insuffi-
ciency and diabetes mellitus may benefit from IOCM.
24-27) 
Furthermore, the concept of expressing the CM-dose as g-I 
was devised to compensate for the concentration of iodine in 
different types of CM. To date, there has been no definite con-
clusion about the difference in the risk of CIN between IOCM 
and LOCM. Further studies with various types of contrast 
agents are warranted to confirm the efficacy of the equation 
in the context of various iodine concentrations.
Conclusions
In cases of elective PCI, the ratio of the amount of systemic 
exposure of CM to eGFR, expressed as g-I/eGFR, has a prog-
nostic value in predicting the occurrence of CIN. Further-
more, the ratio of g-I/eGFR might have a close relationship 
with the development of NRD as well as CIN.
Based on our results, it can be concluded that a ratio of 
g-I/eGFR of <1.42 is a simple, useful indicator for determin-
ing a safe amount of CM based on the pre-procedural eGFR 
values for elective PCI.
A pre-interventional determination of adequate CM-dose, 
based on g-I/eGFR, might be helpful to avoid CIN and NRD.
REFERENCES
1) Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc 
Nephrol 2000;11:177-82.
2) Porter GA. Contrast-associated nephropathy: presentation, patho-
physiology and management. Miner Electrolyte Metab 1994;20:232-43.
3) McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute 
renal failure after coronary intervention: incidence, risk factors, and 
relationship to mortality. Am J Med 1997;103:368-75.
4) McCullough PA, Adam A, Becker CR, et al. Epidemiology and prog-
nostic implications of contrast-induced nephropathy. Am J Cardiol 
2006;98:5K-13K.
5) Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic im-
portance of acute renal failure after percutaneous coronary interven-
tion. Circulation 2002;105:2259-64.
6) Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropa-
thy after percutaneous coronary interventions in relation to chronic 
kidney disease and hemodynamic variables. Am J Cardiol 2005;95: 
13-9.
7) Morcos SK. Contrast media-induced nephrotoxicity: questions and 
answers. Br J Radiol 1998;71:357-65.
8) Lee KH, Lee SR, Kang KP, et al. Periprocedural hemoglobin drop 
and contrast-induced nephropathy in percutaneous coronary inter-
vention patients. Korean Circ J 2010;40:68-73.
9) Namgung J, Doh JH, Lee SY, Hur WS, Park SW, Lee WR. Effect of 
N-acetylcysteine in prevention of contrast-induced nephropathy after 
coronary angiography. Korean Circ J 2005;35:696-701.
10)   Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-an-
alysis: effectiveness of drugs for preventing contrast-induced neph-
ropathy. Ann Intern Med 2008;148:284-94.
11) Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast 
material to prevent contrast nephropathy in patients with renal disease. 
Am J Med 1989;86:649-52.
12) Altmann D, Zwas D, Spatz A, et al. Use of the contrast volume esti-
mated creatinine clearance ratio to predict renal failure after angiogra-
phy. J Interv Cardiol 1997;10:113-9.
13) Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropa-
thy after percutaneous coronary intervention and a method for risk 
stratification. Am J Cardiol 2004;93:1515-9.
14) Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance 
ratio: a pharmacokinetically based risk factor for prediction of early 
creatinine increase after percutaneous coronary intervention. J Am 
Coll Cardiol 2007;50:584-90.
15) Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner 
G. Contrast-medium-Induced nephropathy correlated to the ratio be-
tween dose in gram iodine and estimated GFR in ml/min. Acta Radi-
ol 2005;46:830-42.
16) Kim U, Kim YJ, Lee WJ, et al. The estimated glomerular filtration 
rate with using the Mayo clinic quardratic equation as a new predictor 
for developing contrast induced nephropathy in patients with angina 
pectoris. Korean Circ J 2008;38:301-4.
17) McCullough PA. Contrast-induced acute kidney injury. J Am Coll 
Cardiol 2008;51:1419-28.Hyuck-Jun Yoon, et al.   271
18) Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration 
rate measurements in clinical trials. Modification of Diet in Renal 
Disease Study Group and the Diabetes Control and Complications 
Trial Research Group. J Am Soc Nephrol 1993;4:1159-71.
19) Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more 
accurate method to estimate glomerular filtration rate from serum cre-
atinine: a new prediction equation. Modification of Diet in Renal Dis-
ease Study Group. Ann Intern Med 1999;130:461-70.
20) Frennby B, Sterner G. Contrast media as markers of GFR. Eur Radiol 
2002;12:475-84.
21) Cockcroft DW, Gault MH. Prediction of creatinine clearance from 
serum creatinine. Nephron 1976;16:31-41.
22) Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-
GFR ratio: a measure of systemic exposure to predict contrast-induc-
ed nephropathy after percutaneous coronary intervention. Acta Radiol 
2008;49:658-67.
23) Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- 
and low-osmolality iodinated contrast media. Radiology 1993;188: 
171-8.
24) Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57,925 
patients undergoing coronary procedures using iso-osmolar or low-
osmolar contrast media. Kidney Int 2006;70:1811-7.
25) Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg 
KJ. Nephrotoxic effects in high-risk patients undergoing angiogra-
phy. N Engl J Med 2003;348:491-9.
26) Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of 
contrast media utilization in high-risk PTCA: the COURT trial. Cir-
culation 2000;101:2172-7.
27) Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a 
monomeric nonionic contrast medium on renal function in patients 
with mild to moderate renal insufficiency: a double-blind, randomized 
clinical trial. Eur Radiol 1998;8:144-7.